Larry Anderson, M.D., Ph.D.

Harold C. Simmons Comprehensive Cancer Center

Internal Medicine - Hematology/Oncology
Myeloma Treatment
Monoclonal Gammopathies

New Patient Appointment Accepting Virtual Visits or 214-645-4673

Biography

Larry D. Anderson Jr., M.D., Ph.D., FACP, is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. Additionally, he is the Director of the Myeloma, Waldenström's, and Amyloidosis Program at UTSW’s Harold C. Simmons Comprehensive Cancer Center, where he also leads the Hematologic Malignancies and Cellular Therapy Clinical Research Program. He is also the Co-Director of the Phase I Clinical Trial Research Program and of the Cellular Immunotherapy and Autologous Stem Cell Transplant Program.

Dr. Anderson specializes in the treatment of plasma cell disorders such as multiple myeloma, Waldenström's macroglobulinemia, amyloidosis, and other gammopathies. He treats patients with these diseases at all phases and stages, from diagnosis through stem cell transplant and relapse, and he has a particular interest in CAR T-cell therapy and clinical trials of immunotherapy. He runs an active clinical trial research program that has been a lead enrolling site for many practice-changing myeloma clinical trials (including KarMMa, GRIFFIN, and DETERMINATION), which has helped his program become a world-class center of excellence for plasma cell disorders.

In 2000, Dr. Anderson earned both his medical degree at UT Health Science Center at Houston and his doctoral degree in immunology from MD Anderson Cancer Center and the UTHSC Houston Graduate School of Biomedical Sciences. He completed an internship and residency in internal medicine at the Mayo Clinic, followed by a fellowship in medical oncology at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center, where he later served as a research associate for two years before joining the UT Southwestern faculty in 2008. He is certified is a Diplomate of both the American Board of Internal Medicine and its Subspecialty Board of Medical Oncology and is a Fellow of the American College of Physicians.

In addition, Dr. Anderson is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Society for Transplantation and Cellular Therapy (ASTCT), the International Myeloma Society, the International Society of Amyloidosis, and the Texas Medical Association. He has been named a Texas Monthly Super Doctor every year since 2018 and a D Magazine Best Doctor every year since 2021. He serves on the NCCN Guidelines Panel for plasma cell disorders and on the ASTCT’s Cellular Therapy Committee.

Dr. Anderson’s research interests include cancer immunotherapy, multiple myeloma, and chimeric antigen receptor T-cell (CAR T) therapy. His research has been funded by the American Cancer Society, the National Institutes of Health, the American Society of Clinical Oncology, and the Multiple Myeloma Research Foundation.

Meet Dr. Anderson

Bone Marrow Transplant Specialist

Just a decade ago, patients diagnosed with multiple myeloma were expected to survive only a few years.

The good news is that today’s sophisticated therapies – delivered by experts like Larry D. Anderson Jr., M.D., Ph.D., FACP, at UT Southwestern Medical Center – are helping people with incurable bone marrow cancers like myeloma lead better, longer lives than ever before.

"We provide individualized treatments that consider each patient’s unique circumstances."

Dr. Anderson specializes in plasma cell cancers and bone marrow transplantation. The only oncologist in North Texas to exclusively treat plasma cell cancers, he sees about 90 percent of the myeloma patients who come to UT Southwestern.

He also cares for patients with similar diseases, including Waldenström's macroglobulinemia and amyloidosis.

“I like being able to provide treatments that extend people’s lives and give them a better quality of life, while also working to advance the field by participating in clinical trials that help to develop new treatments,” Dr. Anderson says.

With the current treatments for myeloma, experts estimate the average survival is now eight to 10 years, Dr. Anderson explains. And the latest FDA-approved treatments are more effective and more manageable than traditional chemotherapy.

“It’s been very rewarding to witness the dramatically improved outcomes in my patients over the past several years as new therapies have become available,” Dr. Anderson says.

In addition to offering patients the most innovative therapies and a range of clinical trials for plasma cell disorders, UT Southwestern delivers comprehensive, highly specialized care.

“Having a doctor who sees patients with conditions like theirs exclusively – from their first visit and diagnosis through transplant and long-term follow up – can be a big advantage over seeing a general oncologist who may have only a few myeloma patients,” Dr. Anderson says.

Dr. Anderson is also happy to see plasma cell disorder patients for second opinions to help with guiding treatment decisions, getting them on new therapies on clinical trials, or just for their stem cell transplant process, after which they can return to their referring oncologist if they like.

A number of promising new treatments for plasma cell cancers are currently in clinical trials, Dr. Anderson notes, and UT Southwestern hopes to continue adding more to the list.

"We do the best we can to give patients high-quality lives that are as long as possible,” he says.

Education & Training

Medical School - UT Health Science Center McGovern Medical School (1993-2000)
Internship - Mayo Clinic (2000-2003), Internal Medicine
Fellowship - Fred Hutchinson Cancer Research Center (2003-2006), Medical Oncology